Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.
What does the future hold for new pre-exposure prophylaxis (PrEP) against HIV, including long-acting injectables and less toxic drugs?
The hotly anticipated START trial, designed to answer whether starting HIV treatment at a high CD4 count is preferable to delaying, has been h...
One of the most important drugs in the HIV arsenal is getting a tune-up.
The former AIDSmeds editor-in-chief finds a new role as HIV project director of the Treatment Action Group.
HIV stigma challenges all of us living with the virus to find the strength to live our lives with dignity and hope.
Advocates from the Treatment Action Group (TAG) explain why results of clinical trials should be more transparent.
A Chinese study proves that antiretroviral therapy can indeed reduce transmissions among serodiscordant heterosexual couples.
Saw this picture come up on Facebook via my friend Bob Bowers- this pretty much sums up the AIDS Quilt experience...
The International Association of Physicians in AIDS Care (IAPAC) releases a new guideline, addressing a key issue in the HIV/AIDS epidemic.
POZ on Location: In September, POZ attended the 2010 United States Conference on AIDS (USCA), sponsored by the National Minority AIDS...
Cytheris has announced the launch and recruitment of a new Phase II study of the company’s interleukin-7 (IL-7) drug—combined with the e...
Project Inform has released a statement in response to recent criticism of two papers it released on topic of when to start HIV treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.